Skip to main content

Articles

Page 39 of 39

  1. In a departure from conventional strategies to improve treatment outcome for myeloid malignancies, we report the isolation of leukemia-specific peptides using a phage display library screened with freshly obta...

    Authors: Naomi Galili, Emmanuelle Devemy and Azra Raza
    Citation: Journal of Hematology & Oncology 2008 1:8
    Content type: Research Published on:

  2. To report the clinico-histopathologic features, management and outcome of Rosai-Dorfman disease of the orbit.

    Authors: Geeta K Vemuganti, Milind N Naik and Santosh G Honavar
    Citation: Journal of Hematology & Oncology 2008 1:7
    Content type: Research Published on:

  3. Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic agents. Our laboratory has recently reported that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate, is an inhibitor of HDAC...

    Authors: Quanyi Lu, Xianghua Lin, Jean Feng, Xiangmin Zhao, Ruth Gallagher, Marietta Y Lee, Jen-Wei Chiao and Delong Liu
    Citation: Journal of Hematology & Oncology 2008 1:6
    Content type: Research Published on:

  5. Lipoic acid (LA), a potent antioxidant, has been used as a dietary supplement to prevent and treat many diseases, including stroke, diabetes, neurodegenerative and hepatic disorders. Recently, potent anti-tumo...

    Authors: Elangovan Selvakumar and Tze-chen Hsieh
    Citation: Journal of Hematology & Oncology 2008 1:4
    Content type: Research Published on:

  7. Detection of circulating tumor cells (CTC) in the blood of cancer patients may have prognostic and predictive significance. However, background expression of 'tumor specific markers' in peripheral blood mononu...

    Authors: Fanglei You, Lisa A Roberts, S Peter Kang, Raquel A Nunes, Cinara Dias, J Dirk Iglehart, Natalie A Solomon, Paula N Friedman and Lyndsay N Harris
    Citation: Journal of Hematology & Oncology 2008 1:2
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us